Daily Cardiology Research Analysis
Three clinically impactful cardiology studies stand out today: a meta-analysis of randomized trials shows that very early initiation of SGLT2 inhibitors in acute heart failure reduces all-cause mortality and rehospitalization; a large propensity-matched cohort links early noninvasive cardiac testing after ED evaluation to lower 1-year death/MI across HEART risk strata; and CMR feature-tracking strains independently predict major adverse cardiovascular events in true MINOCA, enhancing risk strati
Summary
Three clinically impactful cardiology studies stand out today: a meta-analysis of randomized trials shows that very early initiation of SGLT2 inhibitors in acute heart failure reduces all-cause mortality and rehospitalization; a large propensity-matched cohort links early noninvasive cardiac testing after ED evaluation to lower 1-year death/MI across HEART risk strata; and CMR feature-tracking strains independently predict major adverse cardiovascular events in true MINOCA, enhancing risk stratification.
Research Themes
- Early pharmacologic optimization in acute heart failure
- Risk stratification via diagnostic testing and imaging
- Translational implementation of evidence into ED and inpatient workflows
Selected Articles
1. Early Initiation of Sodium-Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta-Analysis.
Across seven RCTs (n=2320), starting SGLT2 inhibitors before discharge or within 3 days significantly reduced all-cause mortality (OR 0.71) and heart failure rehospitalization (OR 0.73). Safety outcomes were inconclusive due to low event rates.
Impact: This meta-analysis of RCTs directly supports earlier SGLT2i initiation during AHF admissions, likely accelerating guideline adoption and improving short-term outcomes.
Clinical Implications: Consider initiating SGLT2 inhibitors before discharge for most AHF patients (with usual contraindication checks), incorporating early-start pathways into inpatient heart failure care.
Key Findings
- Early SGLT2i reduced all-cause death (OR 0.71; 95% CI 0.55–0.92).
- Early SGLT2i reduced HF rehospitalizations (OR 0.73; 95% CI 0.57–0.94).
- Efficacy persisted in sensitivity analysis limited to pre-discharge initiation.
- Safety endpoints were underpowered due to low event rates; diabetic-status subgroup effects remain unclear.
Methodological Strengths
- Meta-analysis restricted to randomized controlled trials with prespecified early-initiation window
- Sensitivity analysis (pre-discharge initiation) and adjustment for follow-up duration
Limitations
- Safety endpoints inconclusive due to low event rates and wide confidence intervals
- Limited data to assess effect modification by diabetes status
Future Directions: Large, pragmatic RCTs with standardized early-start protocols and robust safety adjudication are needed, including subgroup analyses by diabetes status and AHF phenotype.
BACKGROUND: Observational studies and small randomized controlled trials have suggested the benefits of early introduction of sodium-glucose cotransporter 2 inhibitors (SGLT2is) in acute heart failure (AHF). However, current evidence on their efficacy and safety in this clinical setting remains limited. METHODS: We performed a systematic review and meta-analysis to assess efficacy/safety of early use of SGLT2is in AHF. PUBMED/EMBASE/Cochrane were searched from inception to May 31, 2024, for randomized controlled trials evaluating outcomes of SGLT2i early initiation in patients with AHF. Efficacy outcomes were all-cause death and heart failure rehospitalizations. Safety outcomes included acute kidney injury, ketoacidosis, urinary tract infections, hypotension, and hypoglycemia. Early initiation was defined as performed before or shortly after discharge (within 3 days). A sensitivity analysis was conducted, including only patients with initiation before discharge. RESULTS: Seven randomized controlled trials that enrolled 2320 patients were included. Early use of SGLT2is was associated with a significant reduction in all-cause death (odds ratio, 0.71 [95% CI, 0.55-0.92; 95% PI, 0.55-0.98]) and HF rehospitalizations (odds ratio, 0.73 [95% CI, 0.57-0.94; 95% PI, 0.58-0.93]), even after adjusting for follow-up duration. SGLT2i initiation before discharge yielded consistent results for efficacy outcomes. Safety outcomes could not be usefully determined because of a low events rate resulting in wide CIs. The impact of diabetic status remains basically unknown due to the small number of available randomized controlled trials investigating this population. CONCLUSIONS: Early introduction of SGLT2is in AHF improves all-cause death and rehospitalization rates, can be performed before discharge, and should be offered to most patients with AHF.
2. Prognostic Value of Strain by Tissue Tracking Cardiac Magnetic Resonance in Myocardial Infarction With Nonobstructive Coronary Arteries.
In 386 patients undergoing CMR, left atrial and ventricular strains varied by MINOCA etiology. In true MINOCA, both LV global longitudinal strain and LA reservoir strain independently predicted MACEs, and their integration improved risk prediction.
Impact: Provides actionable imaging biomarkers for risk stratification in MINOCA, a heterogeneous entity with limited prognostic tools.
Clinical Implications: In MINOCA, incorporate CMR feature-tracking LV GLS and LA reservoir strain to refine prognostication and guide follow-up intensity.
Key Findings
- Among 386 suspected MI patients, strains were lowest in cardiomyopathy etiologies.
- In true MINOCA, LV global longitudinal strain independently predicted MACE (HR 0.90; 95% CI 0.82–0.99).
- Left atrial reservoir strain also independently predicted MACE; combining LA and LV strains enhanced risk prediction.
Methodological Strengths
- CMR feature tracking of both left ventricular and left atrial mechanics
- Event-driven Cox regression with etiologic phenotyping of MINOCA
Limitations
- Single-center, retrospective design limits generalizability
- Heterogeneity of MINOCA etiologies may introduce residual confounding
Future Directions: Prospective multicenter validation of strain thresholds and integration into clinical risk scores for MINOCA care pathways.
BACKGROUND: Strain assessed by cardiac magnetic resonance (CMR) is a key prognostic indicator in myocardial infarction. However, the strain characteristics and prognostic value in myocardial infarction with nonobstructive coronary arteries (MINOCA) with different causes are unclear. This study aims to describe left atrial (LA) and left ventricular strain in patients with MINOCA and evaluate their predictive value for major adverse cardiovascular events (MACEs) in "true MINOCA" cases. METHODS AND RESULTS: This single-center retrospective study included patients suspected of myocardial infarction who completed CMR during hospitalization. CMR images were used to obtain LA and left ventricular strain via CMR feature tracking. True MINOCA was defined by evidence of ischemia or infarction on CMR. MACEs included all-cause death, recurrent myocardial infarction, stroke, heart failure, atrial fibrillation, and angina pectoris. This study included 386 patients, with a median time from admission to CMR of 4 days. LA and left ventricular strains varied by pathogenesis, with the lowest strain in patients with cardiomyopathy. For patients with true MINOCA, Cox regression showed that global longitudinal strain (hazard ratio [HR], 0.90 [95% CI, 0.82-0.99]; CONCLUSIONS: LA and left ventricular strains vary among MINOCA pathogeneses. In true MINOCA patients, global longitudinal strain and LA reservoir strains independently predict MACE risk. Integrating these strains enhances MACE prediction. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT06502899.
3. Association of Early Noninvasive Cardiac Stress Testing With Acute Myocardial Infarction and Mortality.
In 174,917 ED patients with MI ruled out, early noninvasive testing within 72 hours was associated with lower 1-year death/MI across HEART risk strata, with absolute risk reductions of 1.54% (low risk), 4.93% (intermediate), and 8.98% (high risk).
Impact: This large real-world analysis challenges prevailing assumptions by linking early testing to improved outcomes, informing ED pathways and payer policies.
Clinical Implications: For selected patients with ACS ruled out, structured early noninvasive testing pathways may reduce downstream death/MI, especially in intermediate-to-high HEART risk groups.
Key Findings
- Cohort of 174,917 MI-ruled-out ED patients stratified by HEART score.
- Early testing associated with absolute risk reduction in death/MI: −1.54% (NNT=65) low, −4.93% (NNT=20) intermediate, −8.98% (NNT=11) high risk.
- Propensity score analysis used to adjust for confounding across risk strata.
Methodological Strengths
- Very large integrated health system cohort with HEART risk stratification
- Propensity score methodology and absolute risk/NNT reporting by risk strata
Limitations
- Observational design with potential residual confounding and selection bias
- Heterogeneity in testing modality and downstream management not fully characterized
Future Directions: Prospective pragmatic trials to test early-testing pathways vs. usual care across HEART strata, with standardized modalities and downstream management.
STUDY OBJECTIVE: The evaluation for suspected acute coronary syndrome is a common and high-risk presentation in emergency departments (EDs). After exclusion of acute myocardial infarction (MI), patients often undergo early (within 72 hours) noninvasive cardiac testing. We evaluated the association between early noninvasive testing and death/acute MI in ED patients suspected of acute coronary syndrome. METHODS: We used a retrospective cohort study design within the adult ED patient population (from October 2015 to December 2020) in whom MI was ruled out, belonging to a large integrated health care delivery system. Using data on history (H), electrocardiogram (E), age (A), risk factors (R), and troponin (T), we computed the HEART risk score. We stratified the cohort into low (score 0 to 3), intermediate (score 4 to 6), and high (score ≥7) risk and followed them up to 1-year after ED discharge. The association between noninvasive testing within 3 days of the ED visit and composite risk of death/acute MI within 1-year of discharge was evaluated by propensity score analysis. RESULTS: The cohort included 174,917 patients (61% low risk [age 53; women 58%; noninvasive testing 5%], 36% intermediate risk [age 71; women 52%; noninvasive testing 18%], and 3% high risk [age 74, women 45%; noninvasive testing 23%]). The risk reduction in death/acute MI associated with early noninvasive testing was -1.54% (-1.95% to -1.12%) number needed to treat (NNT)=65; -4.93% (-5.66% to -4.20%) NNT=20, and -8.98% (95% confidence interval -11.32% to -6.64%) NNT=11; and, in the low, intermediate, and high-risk respectively. CONCLUSION: Early noninvasive testing was associated with reduced risk of 1-year death or acute MI across all risk groups.